The current evidence regarding the efficacy of tezepelumab administered for asthma on T2-related comorbidities

T2-comorbidities are the most common in severe asthma (SA) patients and have a negative impact on disease outcomes but also an important socio-economic burden. Treating SA and its comorbidities by one medication is a very exciting possibility for the clinicians. Several biologics used for SA showed benefits on T2-comorbidities, but currently more limited data exists for tezepelumab, most recently developed in this domain.

This paper summarizes the available evidence regarding the efficacy of tezepelumab on T2-comorbidities of SA. Electronic search queries were applied to PubMed and Medline databases by using the following terms: 'tezepelumab,' 'severe asthma,' 'allergic rhinitis' (AR), 'chronic rhinosinusitis,' 'nasal polyps' (CRSwNP), 'aspirin exacerbated disease (AERD),' 'atopic dermatitis' (AD), 'eczema,' 'chronique spontaneous urticaria' (CSU),'food allergy' (FA), 'eosinophilic esophagitis' (EE).

Tezepelumab treatment showed undeniable benefits on CRSwNP and AERD by improving sino-nasal and asthma outcomes. If the efficacy of tezepelumab on severe allergic asthma is well documented, current data are insufficient to conclude on its impact on AR. The effects of tezepelumab on AD and CSU were disappointing. No consistent data exists regarding FA and EE. Future studies are needed to confirm the efficacy of tezepelumab on AR, FA, and EE.